Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Larimar Therapeutics (NASDAQ: LRMR) reported Q4 and full‑year 2025 results and provided clinical and financing updates. Key items: Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, topline open‑label data expected Q2 2026, planned BLA submission in June 2026, Phase 3 screening to start Q2 2026, and U.S. launch targeted H1 2027 if approved.
Balance sheet: pro forma cash of $244.5M and projected runway into Q2 2027 after a $107.6M net public offering. Reported full‑year net loss $165.7M; increased R&D investment to support commercialization.
Positive
- Breakthrough Therapy Designation for nomlabofusp (Feb 2026)
- Pro forma cash of $244.5M after February 2026 offering
- Projected cash runway into Q2 2027
- Topline OL study data expected in Q2 2026
- Planned BLA submission seeking accelerated approval in June 2026
Negative
- Full‑year net loss of $165.7M in 2025
- R&D expenses rose to $154.2M for full year 2025
- Q4 2025 net loss widened to $62.5M from $28.8M
News Market Reaction – LRMR
On the day this news was published, LRMR gained 3.95%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $484M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Ahead of this earnings release, LRMR was down 1.83% while momentum peers RCKT and DRUG showed gains of 1.34% and 2.48%. The mixed peer tape and opposite direction suggest a stock-specific setup rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Positive | -15.3% | Q3 2025 results with strong FXN data and BLA plan for Q2 2026. |
| Aug 14 | Q2 2025 earnings | Positive | +14.5% | Q2 2025 results, BLA plan, $203.6M pro forma cash and runway update. |
| Apr 30 | Q1 2025 earnings | Positive | +10.9% | Q1 2025 results with FXN surrogate discussions and strong cash runway. |
| Mar 24 | FY 2024 results | Positive | -10.2% | Full year 2024 results and detailed nomlabofusp development update. |
| Oct 30 | Q3 2024 earnings | Positive | +8.7% | Q3 2024 financials, strong cash of $203.7M, and FA trial milestones. |
Earnings updates with nomlabofusp progress have produced mixed reactions, with both sharp gains and notable selloffs, indicating inconsistent trading responses to similar news.
Over the last five earnings-related updates, Larimar consistently highlighted progress for nomlabofusp in Friedreich’s ataxia and maintained substantial cash balances (e.g., $203.7M, $183.5M, $175.4M, and $203.6M pro forma). BLA timing has gradually shifted from 2H 2025 toward Q2 2026, but the registrational path stayed central. Market reactions ranged from a -15.26% drop to a 14.52% gain, showing that similar clinical and financial messages have not produced a consistent price pattern into or after earnings.
Historical Comparison
Across five prior earnings-style updates, LRMR’s average move was about 1.73%. Today’s pre-news move of -1.83% sits slightly below that average and within the historically mixed reaction range.
Earnings updates have traced nomlabofusp’s path from early discussions of skin FXN as a surrogate endpoint and a targeted 2H 2025 BLA to a refined plan for a BLA in Q2 2026, while cash balances repeatedly supported multi-quarter runways.
Market Pulse Summary
This announcement combines detailed 2025 financials with reaffirmed timelines for nomlabofusp’s BLA in June 2026 and a planned U.S. launch in the first half of 2027, if approved. The company reports $244.5M in pro forma cash and significantly higher R&D spending tied to manufacturing scale‑up and clinical work. Investors may watch upcoming open‑label data, Phase 3 initiation, and ongoing operating losses as key signposts for execution risk.
Key Terms
breakthrough therapy designation regulatory
biologics license application (bla) regulatory
open label study medical
phase 3 confirmatory study medical
upright stability score (uss) medical
surrogate endpoint medical
AI-generated analysis. Not financial advice.
- Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study
- Continued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meeting
- Topline open label study data to support BLA submission expected in Q2 2026
- Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026
- Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved
- Successful closing of
$115 million February 2026 public offering, that included new and existing healthcare focused investors, strengthens balance sheet and extends cash runway $244.5 million in pro forma* cash, cash equivalents and marketable securities as of December 31, 2025, with projected cash runway into the second quarter of 2027
*Pro forma cash, cash equivalents, and marketable securities of
BALA CYNWYD, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2025 operating and financial results.
“This is an exciting and pivotal time for Larimar as we continue advancing nomlabofusp toward registration. Receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA) highlights both the significant unmet needs in Friedreich’s ataxia (FA) and the potential of nomlabofusp to address the underlying frataxin (FXN) deficiency that causes the disabilities experienced by people with FA,” said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. “Importantly, our ongoing engagement with the FDA reinforces our registrational path, and we remain on track to submit our Biologics License Application (BLA) seeking accelerated approval in June 2026. In the second quarter of this year, we expect to report topline data from our open label (OL) study, as well as initiate screening in our global confirmatory Phase 3 study. With a strengthened balance sheet following our recent financing and an extended cash runway into the second quarter of 2027, we are strongly positioned to execute on our registrational milestones over the next 12 months. Nomlabofusp has the potential to become the first disease-modifying therapy for FA, and we are committed to delivering it as rapidly as possible to the FA community who continues to face significant unmet medical need.”
Highlights
- Breakthrough Therapy Designation: In February, the FDA granted Breakthrough Therapy Designation to nomlabofusp for the treatment of adults and children with FA. The designation was based on the FDA’s review of available clinical data from the Company’s ongoing OL study evaluating nomlabofusp in adult and pediatric patients with FA.
- FDA Meeting Comments Support Planned Submission of BLA in June 2026: In February, following a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting with FDA and review of preliminary clinical data for the nomlabofusp program, Larimar announced continued alignment with the FDA on BLA content including:
- FXN as Novel Surrogate Endpoint: FDA reaffirmed willingness to consider use of FXN as novel surrogate endpoint and confirmed that the preliminary exposure-response data presented exploring the relationship between nomlabofusp exposures and clinical outcome measures is the type that can support the future BLA.
- Reference Population: FDA confirmed the process proposed for selecting a reference population based on matched subjects from the Friedrich’s Ataxia Clinical Outcomes Measure Study (FACOMS) database for the natural history comparisons of clinical endpoints to be used for the BLA submission and offered to provide advance review and comment on the proposed statistical plan.
- Safety Dataset: FDA stated that the adequacy of the safety dataset will be a matter of review at the time of BLA submission.
- Global Phase 3 Study: FDA is aligned with plans to have the global confirmatory Phase 3 study underway at the time of BLA submission and confirmed that change from baseline in the Upright Stability Score (USS) (a subscale of mFARS) is a reasonable and clinically relevant primary endpoint for the planned Phase 3 study.
- Strengthened Balance Sheet: In February, Larimar completed a public offering of common stock with net proceeds of
$107.6 million that included new and existing leading healthcare investors, extending its projected cash runway into the second quarter of 2027. - Topline OL Study Data in Second Quarter of 2026: Larimar plans to report topline data from the OL study that is intended to support BLA submission in the second quarter of 2026.
- Global Confirmatory Phase 3 Study: Plan to initiate screening in the second quarter of 2026, with dosing of first patient expected mid-2026.
- BLA Submission on Track: BLA seeking accelerated approval planned to be submitted in June 2026; U.S. launch targeted for first-half 2027, if approved.
Fourth Quarter and Full Year 2025 Financial Results
As of December 31, 2025, the Company had cash, cash equivalents and marketable securities totaling
The Company reported a net loss for the fourth quarter of 2025 of
Research and development expenses for the fourth quarter of 2025 were
General and administrative expenses for both the fourth quarter of 2025 and the fourth quarter of 2024 were
Other income (expense), net was
For the full year 2025, the Company reported a net loss of
Research and development expenses for the full year 2025 were
General and administrative expenses for the full year 2025 were
Other income (expense), net was
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding the timing of the BLA submission, the expectations of the timing of, and potential for, accelerated approval or accelerated access, time to launch and market and overall development plans and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA and Larimar’s ability to timely implement the revised dosing regimen in its clinical program for nomlabofusp; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; Larimar’s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
| Investor Contact: Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com (212) 915-2569 | Company Contact: Michael Celano Chief Financial Officer mcelano@larimartx.com (484) 414-2715 |
| Larimar Therapeutics, Inc. | |||||||
| Consolidated Balance Sheet | |||||||
| (In thousands except share data) | |||||||
| (unaudited) | |||||||
| December 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 85,412 | $ | 33,218 | |||
| Short-term marketable securities | 51,440 | 150,236 | |||||
| Prepaid expenses and other current assets | 5,170 | 11,850 | |||||
| Total current assets | 142,022 | 195,304 | |||||
| Property and equipment, net | 622 | 881 | |||||
| Operating lease right-of-use assets | 2,069 | 2,838 | |||||
| Restricted cash | 606 | 606 | |||||
| Other assets | 523 | 596 | |||||
| Total assets | $ | 145,842 | $ | 200,225 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 5,216 | $ | 2,424 | |||
| Accrued expenses | 58,474 | 20,872 | |||||
| Operating lease liabilities, current | 1,105 | 1,060 | |||||
| Total current liabilities | 64,795 | 24,356 | |||||
| Operating lease liabilities | 2,962 | 4,057 | |||||
| Total liabilities | 67,757 | 28,413 | |||||
| Commitments and contingencies (See Note 8) | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock; 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 250,000*and no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — | |||||
| Common stock, 115,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 83,090,392*and 63,815,065 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 83 | 64 | |||||
| Additional paid-in capital | 512,779 | 440,758 | |||||
| Accumulated deficit | (434,831 | ) | (269,158 | ) | |||
| Accumulated other comprehensive gain | 54 | 148 | |||||
| Total stockholders’ equity | 78,085 | 171,812 | |||||
| Total liabilities and stockholders’ equity | $ | 145,842 | $ | 200,225 | |||
* At December 31, 2025, there were 83,090,392 common shares outstanding and 250,000 shares of Series A Convertible Preferred shares outstanding. The Series A Convertible Preferred shares are non-voting but can be converted at any time at the option of the holder into 2,500,000 shares of Common. On a pro-forma basis, there are 85,590,392 common shares outstanding on an as-converted basis.
| Larimar Therapeutics, Inc. | |||||||||||||||
| Consolidated Statements of Operations | |||||||||||||||
| (In thousands, except share and per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 59,373 | $ | 26,738 | $ | 154,224 | $ | 73,278 | |||||||
| General and administrative | 4,645 | 4,555 | 18,273 | 17,612 | |||||||||||
| Total operating expenses | 64,018 | 31,293 | 172,497 | 90,890 | |||||||||||
| Loss from operations | (64,018 | ) | (31,293 | ) | (172,497 | ) | (90,890 | ) | |||||||
| Other income, net | 1,520 | 2,469 | 6,824 | 10,286 | |||||||||||
| Net loss | $ | (62,498 | ) | $ | (28,824 | ) | $ | (165,673 | ) | $ | (80,604 | ) | |||
| Comprehensive loss: | |||||||||||||||
| Net loss | $ | (62,498 | ) | $ | (28,824 | ) | $ | (165,673 | ) | $ | (80,604 | ) | |||
| Other comprehensive loss: | |||||||||||||||
| Unrealized gain (loss) on marketable securities | (12 | ) | (210 | ) | (94 | ) | 67 | ||||||||
| Total other comprehensive gain (loss) | (12 | ) | (210 | ) | (94 | ) | 67 | ||||||||
| Total comprehensive loss | $ | (62,510 | ) | $ | (29,034 | ) | $ | (165,767 | ) | $ | (80,537 | ) | |||
| Basic and diluted net loss per share | |||||||||||||||
| Common stock | $ | (0.73 | ) | $ | (0.45 | ) | $ | (2.27 | ) | $ | (1.32 | ) | |||
| Preferred stock | $ | (1.19 | ) | $ | — | $ | (1.19 | ) | $ | — | |||||
| Weighted-average shares used in computing basic and diluted net loss per share | |||||||||||||||
| Common stock | 85,182,783 | 63,810,823 | 72,947,927 | 61,256,084 | |||||||||||
| Preferred stock | 250,000 | - | 250,000 | - | |||||||||||
FAQ
What does Larimar's Breakthrough Therapy Designation for nomlabofusp mean for LRMR shareholders?
When will Larimar (LRMR) submit the BLA for nomlabofusp and what is the planned launch timing?
How much cash does Larimar (LRMR) have after the February 2026 public offering and what is the cash runway?
What clinical milestones should investors expect from Larimar (LRMR) in 2026?
How did Larimar's operating expenses change in 2025 and what drove the increase?
